Pharmacological characterization of the selective 11β-hydroxysteroid dehydrogenase 1 inhibitor, BI 135585, a clinical candidate for the treatment of type 2 diabetes.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  European Journal of Pharmacology

• Publication date

  2015-01-05

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ejphar.2014.10.053PMID 25445047
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of 11β-hydroxysteroid dehydrogenase-1 inhibition on hepatic glycogenolysis and gluconeogenesis.

  2013cited by this paper
• 11β-HSD1 Inhibitors for the Treatment of Type 2 Diabetes and Cardiovascular Disease

  2013cited by this paper
• Determinants of glycemic control in youth with type 2 diabetes at randomization in the TODAY study

  2012cited by this paper
• Pioglitazone for diabetes prevention in impaired glucose tolerance.

  2011cited by this paper
• National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants.

  2011cited by this paper
• Effects of an 11β‐hydroxysteroid dehydrogenase type 1 inhibitor, MK‐0916, in patients with type 2 diabetes mellitus and metabolic syndrome

  2011cited by this paper
• Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension.

  2011cited by this paper
• Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11β-hydroxysteroid dehydrogenase type 1.

  2011cited by this paper
• Effect of metformin on cardiovascular events and mortality: a meta‐analysis of randomized clinical trials

  2011cited by this paper
• Effect of 11 beta-hydroxysteroid dehydrogenase-1 inhibition on hepatic glucose metabolism in the conscious dog.

  2010cited by this paper
• The 11-beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy

  2010cited by this paper
• The 11-β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy

  2010cited by this paper
• 11β-Hydroxysteroid Dehydrogenase Type 1 is Overexpressed in Subcutaneous Adipose Tissue of Morbidly Obese Patients

  2009cited by this paper
• Impaired Glucose Tolerance and Insulin Resistance Are Associated With Increased Adipose 11β-Hydroxysteroid Dehydrogenase Type 1 Expression and Elevated Hepatic 5α-Reductase Activity

  2008cited by this paper
• Sub-chronic administration of the 11β-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity

  2008cited by this paper
• Inhibition of 11βHSD1 with the S-phenylethylaminothiazolone BVT116429 increases adiponectin concentrations and improves glucose homeostasis in diabetic KKAy mice

  2008cited by this paper
• 11β‐HSD Type 1 Expression in Human Adipose Tissue: Impact of Gender, Obesity, and Fat Localization

  2007cited by this paper
• Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.

  2007cited by this paper
• Omental 11β‐hydroxysteroid Dehydrogenase 1 Correlates with Fat Cell Size Independently of Obesity

  2007cited by this paper
• Type 2 diabetes and metabolic syndrome are associated with increased expression of 11β-hydroxysteroid dehydrogenase 1 in obese subjects

  2007cited by this paper
• 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients.

  2006cited by this paper
• 11β‐Hydroxysteroid Dehydrogenase Type 1 mRNA is Increased in Both Visceral and Subcutaneous Adipose Tissue of Obese Patients

  2006cited by this paper
• 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.

  2005cited by this paper
• Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice.

  2004cited by this paper
• A Transgenic Model of Visceral Obesity and the Metabolic Syndrome

  2001cited by this paper
• Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation.

  1995cited by this paper
• Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age.

  1987cited by this paper
• Adipose tissue of morbidly obese patients: clinical implications of distribution, morphology, and metabolism.

  1987cited by this paper

• Selective Inhibition of 11beta-Hydroxysteroiddehydrogenase-1 with BI 187004 in Patients with Type 2 Diabetes and Overweight or Obesity: Safety, Pharmacokinetics, and Pharmacodynamics After Multiple Dosing Over 14 Days

  2022cites this paper
• Exploring New Drug Targets for Type 2 Diabetes: Success, Challenges and Opportunities

  2022cites this paper
• Effect of Glucocorticoid and 11β-Hydroxysteroid-Dehydrogenase Type 1 (11β-HSD1) in Neurological and Psychiatric Disorders

  2022cites this paper
• Total Synthesis of Terpenes and Their Biological Significance: A Critical Review

  2022cites this paper
• Total Synthesis of the Meroterpenoid Manginoid A as Fueled by a Challenging Pinacol Coupling and Bicycle-forming Etherification.

  2021cites this paper
• Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 as Potential Drugs for Type 2 Diabetes Mellitus—A Systematic Review of Clinical and In Vivo Preclinical Studies

  2021cites this paper
• Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesity

  2020cites this paper
• Progress in 11β-HSD1 inhibitors for the treatment of metabolic diseases: A comprehensive guide to their chemical structure diversity in drug development.

  2020cites this paper
• Benzannulated spiroketal natural products: isolation, biological activity, biosynthesis, and total synthesis.

  2019cites this paper
• Role of Hepatic Glucocorticoid Receptor in Metabolism in Models of 5αR1 Deficiency in Male Mice

  2019cites this paper
• Discovery of Potent Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 Using a Novel Growth-Based Protocol of in Silico Screening and Optimization in CONTOUR

  2019cites this paper
• Pentacyclic Triterpenes from Cecropia telenitida Can Function as Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1

  2018cites this paper
• Invitro and Invivo Inhibition of Metyrapone Metabolism by Glycyrrhetinic Acid in Male Wistar Rats

  2017cites this paper
• Virtual screening applications in short-chain dehydrogenase/reductase research.

  2017cites this paper
• Manginoids A-G: Seven Monoterpene-Shikimate-Conjugated Meroterpenoids with a Spiro Ring System from Guignardia mangiferae.

  2017cites this paper
• 11&bgr;‐Hydroxysteroid Dehydrogenase Type 1 in Obese Subjects With Type 2 Diabetes Mellitus

  2017cites this paper
• Impact of Adrenal Steroids on Regulation of Adipose Tissue.

  2017cites this paper
• Potent and selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1 labeled with carbon-13 and carbon-14.

  2017cites this paper
• Discovery of BI 135585, an in vivo efficacious oxazinanone-based 11β hydroxysteroid dehydrogenase type 1 inhibitor.

  2017cites this paper
• Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β‐hydroxysteroid dehydrogenase‐1 (HSD1) inhibitor in humans: liver and adipose tissue 11β‐HSD1 inhibition after acute and multiple administrations over 2 weeks

  2016cites this paper
• Novel small molecule 11β-HSD1 inhibitor from the endophytic fungus Penicillium commune

  2016influential citation
• The increased ratio of 11β-hydroxysteroid dehydrogenase type 1 versus 11β-hydroxysteroid dehydrogenase type 2 in chronic periodontitis irrespective of obesity

  2016cites this paper
• Discovery of 2-((R)-4-(2-Fluoro-4-(methylsulfonyl)phenyl)-2-methylpiperazin-1-yl)-N-((1R,2s,3S,5S,7S)-5-hydroxyadamantan-2-yl)pyrimidine-4-carboxamide (SKI2852): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1).

  2016cites this paper
• A one-pot synthesis of 1,6,9,13-tetraoxadispiro(4.2.4.2)tetradecane by hydrodeoxygenation of xylose using a palladium catalyst.

  2016cites this paper
• Influence of sub-chronic selective 11β-hydroxysteroid dehydrogenase 1 inhibition on the hypothalamic-pituitary-adrenal axis in female cynomolgus monkeys.

  2016cites this paper
• A potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, SKI2852, ameliorates metabolic syndrome in diabetic mice models.

  2015cites this paper
• 1,3-Oxazines and Their Benzo Derivatives

  2008cites this paper
• Evolving Novel Drug Targets For Type 2 Diabetes: A Mechanistic Approach towards - Success, Challenges and Opportunities

  year unknowncites this paper